ABOUT US

QUALITY OF LIFE WITH A CHRONIC INFLAMMATORY DISEASE

Lipum AB (publ) is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully humanized antibody designed to give safer and more efficacious therapy by blocking a previously overlooked target molecule of the immune system.

Supported by solid pre-clinical data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis Lipum is exploring a range of other diseases with a high unmet medical need. We intend to show clinical proof of concept for SOL-116. This will enable a long-term sustainable business model through strategic partnerships.

Based in Umeå, an excellent life science cluster in Sweden, Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.

ABOUT US

OTHER MARKET MATERIAL

Einar Pontén presents Lipum at Naventus Life Science Summit. September 2021.

Click to enlarge images.

Biostock interviews Einar Pontén, CEO Lipum. September 2021.

Lennart Lundberg Joins Lipum’s Scientific Advisory Board. Read more »

Watch our CEO Einar Pontén present Lipum at the spring edition of BioStock Life Science Summit 2021.

Einar Pontén, CEO Lipum, presents the recent progress in bringing our lead candidate SOL-116 towards clinical verification At Biostock Life Science Summit, November 2020 (Time 14:02)

BioStock interview with Einar Pontén, CEO Lipum, at the LSX World Congress in London, February 2020. (Time 4:33)

Interview with Ulf Björklund, Chairman of the Board Lipum, at BIO-Europe 2019 in Hamburg. (Time 6:28)

ABOUT US